Back to Journals » Drug Design, Development and Therapy » Volume 9

Pentoxifylline and electromagnetic field improved bone fracture healing in rats

Authors Atalay Y, Gunes N, Guner MD, Akpolat V, Celik MS, Guner R

Received 1 June 2015

Accepted for publication 28 July 2015

Published 9 September 2015 Volume 2015:9 Pages 5195—5201

DOI https://doi.org/10.2147/DDDT.S89669

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Wei Duan


Yusuf Atalay,1 Nedim Gunes,2 Mehmet Dervis Guner,3 Veysi Akpolat,4 Mustafa Salih Celik,4 Rezzan Guner2

1
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Afyon Kocatepe University, Afyonkarahisar, 2Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Dicle University, Diyarbakir, 3Department of Orthopedics, Medicana Hospitals, Ankara, 4Department of Biophysics, Faculty of Medicine, Dicle University, Diyarbakir, Turkey

Background:
The aim of this study was to evaluate the effects of a phosphodiesterase inhibitor pentoxifylline (PTX), electromagnetic fields (EMFs), and a mixture of both materials on bone fracture healing in a rat model.
Materials and methods: Eighty male Wistar rats were randomly divided into four groups: Group A, femur fracture model with no treatment; Group B, femur fracture model treated with PTX 50 mg/kg/day intraperitoneal injection; Group C, femur fracture model treated with EMF 1.5±0.2 Mt/50 Hz/6 hours/day; and Group D, femur fracture model treated with PTX 50 mg/kg/day intraperitoneal injection and EMF 1.5±0.2 Mt/50 Hz/6 hours/day.
Results: Bone fracture healing was significantly better in Group B and Group C compared to Group A (P<0.05), but Group D did not show better bone fracture healing than Group A (P>0.05).
Conclusion: It can be concluded that both a specific EMF and PTX had a positive effect on bone fracture healing but when used in combination, may not be beneficial.

Keywords:
bones, electromagnetic fields, fracture healing, phosphodiesterase inhibitor, pentoxifylline, rats

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]